Tom Nolan’s research reviews—28 July 2022

The tides are coming inA 20% reduction in weight at 72 weeks, as seen in a new study of the dual GIP and GLP-1 agonist tirzepatide, is comparable with results from bariatric surgery. This phase 3 double blind placebo controlled trial recruited 2539 adults with a body mass index (BMI) >30 or BMI >27 with one or more weight related complications. Mean weight loss in the placebo group was 3.1%, compared with 15% with a 5 mg weekly injection of tirzepatide, and 20.9% with a 15 mg dose. Side effects of nausea, diarrhoea, and constipation were common, but dropout rates were low, at 10-15%. Drugs for obesity have a habit of being withdrawn because of risks to cardiovascular health, and while no difference was seen in major cardiovascular events between placebo and tirzepatide in this study, the participants were recruited from a relatively low risk population, and the study didn’t…
Read Original Article: Tom Nolan’s research reviews—28 July 2022 »